drugset / Trial / NCT00659750

To Assess the Safety and Efficacy of Ciclesonide Applied as a Nasal Spray in the Treatment of Perennial Allergic Rhinitis (BY9010/M1-402)

NCT00659750

Phase 3 Completed 418 enrolled AstraZeneca
RandomizedParallel-groupTriple-blindTreatment

Summary

The primary objective of this study is to demonstrate the efficacy of ciclesonide applied as a nasal spray once daily in patients with PAR. The secondary objectives are to evaluate Quality-of-Life and safety.

Timeline

Start
2003-12
Primary completion
2004-05
Completion
2005-04

Drugs

EvaluationDrugModalityDoseRoute
Comparator Ciclesonide Other / unclassified 200 ug Intranasal